Literature DB >> 22592135

The application and mechanism of action of ribavirin in therapy of hepatitis C.

Emmanuel Thomas1, Marc G Ghany, T Jake Liang.   

Abstract

Ribavirin has been used as an antiviral agent for several decades. Although it has activity against numerous viruses, its major use clinically has been in the treatment of respiratory syncytial virus in paediatric patients and chronic HCV infection in both children and adults. This review highlights the clinical application and mechanism of action of ribavirin and discusses the future role of ribavirin in treatment of HCV where there are intense research efforts to improve therapy.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22592135      PMCID： PMC6271563          DOI： 10.3851/IMP2125

Source DB:  PubMed          Journal:  Antivir Chem Chemother        ISSN： 0956-3202


  123 in total

1.  Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report.

Authors:  J H Hoofnagle; K D Mullen; D B Jones; V Rustgi; A Di Bisceglie; M Peters; J G Waggoner; Y Park; E A Jones
Journal:  N Engl J Med       Date:  1986-12-18       Impact factor: 91.245

Review 2.  Second-wave protease inhibitors: choosing an heir.

Authors:  Sandra Ciesek; Thomas von Hahn; Michael P Manns
Journal:  Clin Liver Dis       Date:  2011-06-25       Impact factor: 6.126

3.  Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads.

Authors:  K Rajender Reddy; Mitchell L Shiffman; Maribel Rodriguez-Torres; Hugo Cheinquer; Djamal Abdurakhmanov; Igor Bakulin; Viacheslav Morozov; Giovanni Faria Silva; Natalia Geyvandova; Carol Stanciu; Michael Rabbia; Michael McKenna; James A Thommes; Stephen A Harrison
Journal:  Gastroenterology       Date:  2010-09-30       Impact factor: 22.682

4.  Characterization of ribavirin uptake systems in human hepatocytes.

Authors:  Yukina Fukuchi; Tomomi Furihata; Misato Hashizume; Minami Iikura; Kan Chiba
Journal:  J Hepatol       Date:  2010-02-04       Impact factor: 25.083

5.  Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon alpha-2b and ribavirin combination after liver transplantation.

Authors:  J Dumortier; E Ducos; J-Y Scoazec; P Chevallier; O Boillot; M-C Gagnieu
Journal:  J Viral Hepat       Date:  2006-08       Impact factor: 3.728

6.  Modelling how ribavirin improves interferon response rates in hepatitis C virus infection.

Authors:  Narendra M Dixit; Jennifer E Layden-Almer; Thomas J Layden; Alan S Perelson
Journal:  Nature       Date:  2004-12-16       Impact factor: 49.962

7.  Ribavirin regulates hepatitis C virus replication through enhancing interferon-stimulated genes and interleukin 8.

Authors:  Yoshio Tokumoto; Yoichi Hiasa; Kazuhiro Uesugi; Takao Watanabe; Toshie Mashiba; Masanori Abe; Teru Kumagi; Yoshio Ikeda; Bunzo Matsuura; Morikazu Onji
Journal:  J Infect Dis       Date:  2012-02-21       Impact factor: 5.226

Review 8.  Mechanism of action of interferon and ribavirin in treatment of hepatitis C.

Authors:  Jordan J Feld; Jay H Hoofnagle
Journal:  Nature       Date:  2005-08-18       Impact factor: 49.962

9.  Ribavirin up-regulates the activity of double-stranded RNA-activated protein kinase and enhances the action of interferon-alpha against hepatitis C virus.

Authors:  Wei-Liang Liu; Wen-Cheng Su; Ching-Wei Cheng; Lih-Hwa Hwang; Chih-Chiang Wang; Hui-Ling Chen; Ding-Shinn Chen; Ming-Yang Lai
Journal:  J Infect Dis       Date:  2007-06-25       Impact factor: 5.226

10.  An orally available, small-molecule interferon inhibits viral replication.

Authors:  Hideyuki Konishi; Koichi Okamoto; Yusuke Ohmori; Hitoshi Yoshino; Hiroshi Ohmori; Motooki Ashihara; Yuichi Hirata; Atsunori Ohta; Hiroshi Sakamoto; Natsuko Hada; Asao Katsume; Michinori Kohara; Kazumi Morikawa; Takuo Tsukuda; Nobuo Shimma; Graham R Foster; William Alazawi; Yuko Aoki; Mikio Arisawa; Masayuki Sudoh
Journal:  Sci Rep       Date:  2012-02-10       Impact factor: 4.379
View more
  38 in total

Review 1.  Polymerases of paramyxoviruses and pneumoviruses.

Authors:  Rachel Fearns; Richard K Plemper
Journal:  Virus Res       Date:  2017-01-16       Impact factor: 3.303

2.  The IMPDH inhibitors, ribavirin and mycophenolic acid, inhibit peste des petits ruminants virus infection.

Authors:  Qiu-Yan Chang; Fu-Cheng Guo; Xue-Rui Li; Jian-Hua Zhou; Xuepeng Cai; Qiuwei Pan; Xiao-Xia Ma
Journal:  Vet Res Commun       Date:  2018-08-09       Impact factor: 2.459

3.  A multifaceted computational report on the variants effect on KIR2DL3 and IFNL3 candidate gene in HCV clearance.

Authors:  Pratichi Singh; J Febin Prabhu Dass
Journal:  Mol Biol Rep       Date:  2016-07-26       Impact factor: 2.316

4.  IMPDH inhibitors for antitumor therapy in tuberous sclerosis complex.

Authors:  Alexander J Valvezan; Molly C McNamara; Spencer K Miller; Margaret E Torrence; John M Asara; Elizabeth P Henske; Brendan D Manning
Journal:  JCI Insight       Date:  2020-04-09

5.  Repurposing of Ribavirin as an Adjunct Therapy against Invasive Candida Strains in an In Vitro Study.

Authors:  Hanane Yousfi; Carole Cassagne; Stéphane Ranque; Jean-Marc Rolain; Fadi Bittar
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

Review 6.  Current and future therapies for hepatitis C virus infection.

Authors:  T Jake Liang; Marc G Ghany
Journal:  N Engl J Med       Date:  2013-05-16       Impact factor: 91.245

Review 7.  Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIV.

Authors:  Christine E MacBrayne; Jennifer J Kiser
Journal:  Clin Infect Dis       Date:  2016-07-15       Impact factor: 9.079

8.  Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C.

Authors:  Yaron Rotman; Mazen Noureddin; Jordan J Feld; Jeremie Guedj; Michael Witthaus; Hwalih Han; Yoon J Park; Su-Hyung Park; Theo Heller; Marc G Ghany; Edward Doo; Christopher Koh; Adil Abdalla; Naveen Gara; Souvik Sarkar; Emmanuel Thomas; Golo Ahlenstiel; Birgit Edlich; Rachel Titerence; Leah Hogdal; Barbara Rehermann; Harel Dahari; Alan S Perelson; Jay H Hoofnagle; T Jake Liang
Journal:  Gut       Date:  2013-02-08       Impact factor: 23.059

9.  Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir.

Authors:  Curtis Cooper; Susanna Naggie; Michael Saag; Jenny C Yang; Luisa M Stamm; Hadas Dvory-Sobol; LingLing Han; Phillip S Pang; John G McHutchison; Douglas Dieterich; Mark Sulkowski
Journal:  Clin Infect Dis       Date:  2016-05-25       Impact factor: 9.079

Review 10.  Telaprevir/boceprevir era: from bench to bed and back.

Authors:  Qiuwei Pan; Maikel P Peppelenbosch; Harry L A Janssen; Robert J de Knegt
Journal:  World J Gastroenterol       Date:  2012-11-21       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.